| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4001984 | American Journal of Ophthalmology | 2015 | 7 Pages |
Abstract
AR-13324 ophthalmic solution 0.2%, administered once daily in the morning for 8Â days, produced little or no quantifiable systemic exposure to the parent compound or a presumed metabolite. Clinically and statistically significant reductions in intraocular pressure were observed in these normotensive subjects that were more pronounced compared with what has been observed commonly with other ocular hypotensive therapies in this population.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Brian Levy, Nancy Ramirez, Gary D. Novack, Casey Kopczynski,